Xenon Pharmaceuticals Inc. (XENE) AI Stock Analysis

Xenon Pharmaceuticals Inc. is a Canada-based biopharmaceutical company founded in 1996 that focuses on developing novel therapies for neurological disorders. Its clinical pipeline includes XEN496, a Kv7 potassium channel opener in Phase III trials for KCNQ2 developmental and epilepsy encephalopathy, and XEN1101, also a Kv7 potassium channel opener progressing through Phase II trials for epilepsy. The company is also evaluating NBI-921352 in Phase II trials for SCN8A developmental and epileptic encephalopathy through a partnership with Neurocrine Biosciences, Inc. Additionally, its pipeline features XEN007 in Phase II clinical trials and a collaboration with Flexion Therapeutics, Inc. to develop PCRX301 for post-operative pain.

Xenon Pharmaceuticals recorded annual revenue of $7.5M in FY2025, which declined 20.5% from $9.4M in FY2022 and down from $32.2M in FY2020. Gross margin in FY2025 was 66.1%, down from 100.0% in earlier fiscal years. Operating loss widened as research and development expenses expanded to $300.9M in FY2025, leading to an operating margin of -4974.3% and a net loss of -$345.9M, or -$4.36 per share. For the trailing twelve months ended June 30, 2026, revenue stood at $0, reflecting a quarterly revenue decline of 100.0% year-over-year and an EPS of -$4.74.

As of June 30, 2026, Xenon Pharmaceuticals held $930.7M in cash and short-term investments against total debt of $6.4M, resulting in net cash of $924.3M. The company's current ratio was 21.02, and its debt-to-equity ratio was 0.01 on shareholders' equity of $1.24B. Operating cash flow was -$279.1M in FY2025, while free cash flow stood at -$279.9M after accounting for capital expenditures of $799,000. Over five years, the company's share count expanded by 141.8%.

At a share price of $33.49 as of October 16, 2026, Xenon Pharmaceuticals has a market capitalization of $3.24B and an enterprise value of $2.62B. The stock trades at a price-to-book ratio of 3.0x, a price-to-sales ratio of 727.4x, and an EV-to-EBITDA ratio of 34.2x. These valuation multiples exceed the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x and an EV-to-EBITDA multiple of 12.0x. Over the past year, XENE declined 20.6%, trailing the S&P 500 return of 16.8%.

Wall Street coverage includes 15 Strong Buy, 3 Buy, and 1 Hold recommendations, with no Sell or Strong Sell ratings. The mean price target is $72.42, which implies an upside of 116.3% over the last close of $33.49. For the current fiscal year ending December 31, 2026, consensus expectations project revenue of $1.3M and an EPS of -$4.63. For the following fiscal year, 14 analysts expect revenue of $27.0M and an EPS of -$4.72. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of Xenon Pharmaceuticals Inc. (XENE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: XENE income statement, XENE balance sheet, XENE key metrics, XENE analyst forecast, XENE chart. See the XENE stock overview for the latest quote and news.